OneCell Diagnostics
OneCell Diagnostics develops genomic and AI-driven liquid biopsy tests to improve cancer diagnosis, monitoring, and clinical decision-making. The company combines Next-Generation Sequencing (NGS), circulating tumor cell (CTC) detection, and AI/ML multi-omics analytics to deliver lab-developed tests including Onco Indx (genomic profiling), Onco Discover (CTC detection), and Onco Monitor (disease monitoring). Its platform integrates single‑cell multi-omics biomarker analysis with bioinformatics to generate actionable insights for oncologists and clinical trial teams. OneCell primarily serves healthcare providers, oncologists, and biotech/pharma companies involved in clinical care and early-stage trials.
OneCell Diagnostics
OneCell Diagnostics develops genomic and AI-driven liquid biopsy tests to improve cancer diagnosis, monitoring, and clinical decision-making. The company combines Next-Generation Sequencing (NGS), circulating tumor cell (CTC) detection, and AI/ML multi-omics analytics to deliver lab-developed tests including Onco Indx (genomic profiling), Onco Discover (CTC detection), and Onco Monitor (disease monitoring). Its platform integrates single‑cell multi-omics biomarker analysis with bioinformatics to generate actionable insights for oncologists and clinical trial teams. OneCell primarily serves healthcare providers, oncologists, and biotech/pharma companies involved in clinical care and early-stage trials.